| Title |
Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease
|
|---|---|
| Published in |
Psychopharmacology, October 1993
|
| DOI | 10.1007/bf02244889 |
| Pubmed ID | |
| Authors |
Timothy T. Soncrant, Kathleen C. Raffaele, Sanjay Asthana, Annamaria Berardi, P. Pearse Morris, James V. Haxby |
| Abstract |
Arecoline, a cholinergic agonist, administered at low doses by continuous intravenous infusion for up to 2 weeks, significantly and replicably improved memory in five of nine subjects with mild-moderate Alzheimer's disease. During dose finding, performance on a verbal memory task improved with an inverted U-shaped relation to dose. Six of nine subjects were classified as responders. During blinded, placebo-controlled, individualized optimal dosing for 5 days, verbal memory again improved in five of six responders but not in any non-responder. No adverse drug effects occurred. Arecoline, and possibly other cholinergic agonists, can safely improve memory in Alzheimer's disease at doses much lower than previously studied. |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Finland | 1 | 2% |
| New Zealand | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 40 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 26% |
| Student > Master | 6 | 14% |
| Unspecified | 4 | 9% |
| Professor > Associate Professor | 4 | 9% |
| Student > Ph. D. Student | 4 | 9% |
| Other | 8 | 19% |
| Unknown | 6 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 7 | 16% |
| Biochemistry, Genetics and Molecular Biology | 5 | 12% |
| Unspecified | 4 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Medicine and Dentistry | 4 | 9% |
| Other | 9 | 21% |
| Unknown | 10 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2015.
All research outputs
#8,247,081
of 25,383,344 outputs
Outputs from Psychopharmacology
#2,154
of 5,328 outputs
Outputs of similar age
#5,656
of 19,616 outputs
Outputs of similar age from Psychopharmacology
#8
of 19 outputs
Altmetric has tracked 25,383,344 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 5,328 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 19,616 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.